Our analyses demonstrated a significant increase of PD‐1, the target of monoclonal antibody (pembrolizumab) approved for late‐stage GC and a marker of tumor‐reactive T cells and enhanced T‐cell receptor signaling,54 in the OMIRPS‐low subgroup. Here, PDCD1 is linked to neoplasm.